The translational potential of the lung microbiome as a biomarker and a therapeutic target for chronic obstructive pulmonary disease

Author:

Yang Lei1,Li Naijian23,Yi Xinzhu1,Wang Zhang1ORCID

Affiliation:

1. Biomedical Research Center Institute of Ecological Sciences School of Life Sciences South China Normal University Guangzhou Guangdong China

2. Department of Allergy and Clinical Immunology State Key Laboratory of Respiratory Disease National Center for Respiratory Medicine Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong China

3. Johns Hopkins Asthma and Allergy Center Johns Hopkins University School of Medicine Baltimore Maryland USA

Abstract

AbstractChronic obstructive pulmonary disease (COPD) is a major chronic lung disease with a leading global morbidity and mortality. Emerging evidence suggests that the lung microbiome, the collection of the microorganisms in the lung, plays a crucial role in COPD pathogenesis. The lung microbiome alters in COPD during the acute exacerbations, associates with clinical phenotypes and inflammatory endotypes, and predicts treatment response, lung function decline and mortality, suggesting it could be a potential biomarker for COPD phenotyping, prognosis and personalized therapies. The lung microbiome produces metabolites that interact with host immunity and contribute to COPD pathogenesis, implying that it could be a possible novel target for therapeutic intervention. Despite these potentials, critical gaps exist for translational application of the lung microbiome in COPD clinical practice, starting with the lack of approaches in precisely measuring and manipulating specific members of the lung microbiome, highlighting the need for future collaborative efforts from bench to bedsides. In this perspective, we review existing knowledge and progress on the understanding of the lung microbiome as a possible COPD biomarker or a therapeutic target. We discuss current challenges and share our views on future directions toward fully realize the potential in translational application of the lung microbiome in the promise of COPD precision medicine.

Publisher

Wiley

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3